세계의 디지털 바이오마커 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2025-2033년)

Global Digital Biomarkers Market size is anticipated to grow from USD 4.74 Billion in 2024 to USD 30.32 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 22.91% during the forecast period of 2026 to 2033.

The Digital Biomarkers Market is rapidly expanding as advancements in technology enable the development of innovative solutions for health monitoring and disease management. Digital biomarkers, which are objective, quantifiable physiological and behavioral data collected through digital devices, are transforming how healthcare providers assess patient health and treatment efficacy. By leveraging wearables, mobile applications, and remote monitoring tools, healthcare professionals can gain real-time insights into patient conditions, leading to more personalized and proactive care.

Moreover, the integration of artificial intelligence and machine learning into digital biomarker analysis is enhancing the accuracy and predictive capabilities of these tools. AI algorithms can analyze vast amounts of data to identify patterns and correlations that may not be apparent through traditional methods, enabling earlier detection of health issues and more effective interventions. This shift towards data-driven healthcare is empowering patients to take an active role in managing their health, fostering greater engagement and adherence to treatment plans.

Additionally, the growing emphasis on preventive healthcare and chronic disease management is driving demand for digital biomarkers. As healthcare systems worldwide seek to reduce costs and improve outcomes, the ability to monitor health metrics remotely and continuously is becoming increasingly valuable. Digital biomarkers can facilitate timely interventions, reduce hospitalizations, and enhance overall patient quality of life.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Type

• Wearable
• Mobile Based Applications
• Sensors
• Others

By Clinical Practice

• Diagnostic Digital Biomarkers
• Monitoring Digital Biomarkers
• Predictive And Prognostic Digital Biomarkers
• Other's

By Therapeutic Area

• Cardiovascular And Metabolic Disorders (CVMD)
• Respiratory Disorders
• Psychiatric Disorders
• Sleep & Movement Disease
• Neurological Disorders
• Musculoskeletal Disorders
• Others

By End-use

• Healthcare Companies
• Healthcare Providers
• Payers
• Others
• COMPANIES PROFILED
• Amgen Inc.
• Biogen Inc.
• ActiGraph LLC
• AliveCor Inc.
• Empatica Inc.
• IXICO plc
• Neurotrack Technologies Inc.
• Clario
• Koneksa
• Huma
• Sonde Health Inc.
• Aural Analytics
• Adherium Limited
• Imagene AI
• Brainomix
• The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. DIGITAL BIOMARKERS INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Poerter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By Clinical Practice
  • 3.7.3 Market Attractiveness Analysis By Therapeutic Area
  • 3.7.4 Market Attractiveness Analysis By End-use
  • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL DIGITAL BIOMARKERS MARKET ANALYSIS BY TYPE

• 5.1. Overview By Type
• 5.2. Historical and Forecast Data Analysis By Type
• 5.3. Wearable Historic and Forecast Sales By Regions
• 5.4. Mobile Based Applications Historic and Forecast Sales By Regions
• 5.5. Sensors Historic and Forecast Sales By Regions
• 5.6. Others Historic and Forecast Sales By Regions

6. GLOBAL DIGITAL BIOMARKERS MARKET ANALYSIS BY CLINICAL PRACTICE

• 6.1. Overview By Clinical Practice
• 6.2. Historical and Forecast Data Analysis By Clinical Practice
• 6.3. Diagnostic Digital Biomarkers Historic and Forecast Sales By Regions
• 6.4. Monitoring Digital Biomarkers Historic and Forecast Sales By Regions
• 6.5. Predictive And Prognostic Digital Biomarkers Historic and Forecast Sales By Regions
• 6.6. Other's Historic and Forecast Sales By Regions

7. GLOBAL DIGITAL BIOMARKERS MARKET ANALYSIS BY THERAPEUTIC AREA

• 7.1. Overview By Therapeutic Area
• 7.2. Historical and Forecast Data Analysis By Therapeutic Area
• 7.3. Cardiovascular And Metabolic Disorders (CVMD) Historic and Forecast Sales By Regions
• 7.4. Respiratory Disorders Historic and Forecast Sales By Regions
• 7.5. Psychiatric Disorders Historic and Forecast Sales By Regions
• 7.6. Sleep & Movement Disease Historic and Forecast Sales By Regions
• 7.7. Neurological Disorders Historic and Forecast Sales By Regions
• 7.8. Musculoskeletal Disorders Historic and Forecast Sales By Regions
• 7.9. Others Historic and Forecast Sales By Regions

8. GLOBAL DIGITAL BIOMARKERS MARKET ANALYSIS BY END-USE

• 8.1. Overview By End-use
• 8.2. Historical and Forecast Data Analysis By End-use
• 8.3. Healthcare Companies Historic and Forecast Sales By Regions
• 8.4. Healthcare Providers Historic and Forecast Sales By Regions
• 8.5. Payers Historic and Forecast Sales By Regions
• 8.6. Others Historic and Forecast Sales By Regions

9. GLOBAL DIGITAL BIOMARKERS MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE DIGITAL BIOMARKERS COMPANIES

• 10.1. Digital Biomarkers Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF DIGITAL BIOMARKERS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Amgen Inc.
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Biogen Inc.
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. ActiGraph LLC
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. AliveCor Inc.
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. Empatica Inc.
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. IXICO Plc
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. Neurotrack Technologies Inc.
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Clario
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. Koneksa
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Huma
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. Sonde Health Inc.
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments
• 11.14. Aural Analytics
  • 11.14.1 Company Overview
  • 11.14.2 Company Revenue
  • 11.14.3 Products
  • 11.14.4 Recent Developments
• 11.15. Adherium Limited
  • 11.15.1 Company Overview
  • 11.15.2 Company Revenue
  • 11.15.3 Products
  • 11.15.4 Recent Developments
• 11.16. Imagene AI
  • 11.16.1 Company Overview
  • 11.16.2 Company Revenue
  • 11.16.3 Products
  • 11.16.4 Recent Developments
• 11.17. Brainomix
  • 11.17.1 Company Overview
  • 11.17.2 Company Revenue
  • 11.17.3 Products
  • 11.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies